Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1196 of 5804
-
New CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowEvaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
Phase: EARLY_PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New radiation technique aims to zap prostate cancer with fewer side effects
Disease control Recruiting nowThe goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time. The main questions this trial aims to answer are: …
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for tough lymphoma: experimental drug AZD4512 enters human trials
Disease control Recruiting nowThis is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug plus chemo enters early trial
Disease control OngoingPancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic c…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Ear zap may cut ICU stays and costs for brain injury patients
Disease control Recruiting nowThis study will demonstrate the impact of taVNS on reducing adverse events in NeuroICU patients, determine if taVNS reduces length of stay, and quantify the economic benefits of taVNS implementation in a broader neurocritical care population.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Tiny bladder implant could free patients from catheters
Disease control Recruiting nowThe goal of this study is to check if the study device, the Akyva System, is safe to use and to find out if it has any possible side effects. Researchers will see if the study device can help you urinate without the need for catheterization, which involves passing a catheter (sma…
Phase: NA • Sponsor: Iota Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Timing is everything: new trial seeks best moment for blood thinners after stroke
Disease control Recruiting nowThis study evaluates the safety and efficacy of early versus delayed initiation of direct oral anticoagulants (DOACs) in patients with acute ischemic stroke related to atrial fibrillation who develop hemorrhagic transformation after endovascular treatment.
Phase: NA • Sponsor: Capital Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Dental checkups every 3 months may save cancer Survivors' teeth and smiles
Disease control Not yet recruitingThe goal of this clinical trial is to learn if an oral care programme can prevent or reduce late oral side effects in patients with head and neck cancer following treatment. The main questions it aims to answer are: * Can additional support from hospital dental care for cancer s…
Phase: NA • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 26, 2026 17:26 UTC
-
New drug firsekibart takes on anakinra in Still's disease showdown
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of firsekibart versus anakinra in patients with AOSD.
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for toddlers with aggressive brain cancer: experimental spinal-fluid chemo
Disease control Recruiting nowPilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.
Phase: EARLY_PHASE1 • Sponsor: C17 Council • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a gut bacteria pill tame immunotherapy side effects?
Disease control Recruiting nowImmune-related colitis from immune checkpoint inhibitors (ICI) is a common adverse effect causing significant morbidity and impairment of quality of life (QoL). Steroids are the first line of treatment for severe ICI induced Immune- mediated diarrhea and colitis (IMDC). If there …
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Cell injection aims to repair damaged livers in early trial
Disease control ENROLLING_BY_INVITATIONThree sequential dose cohorts are predefined for single administration: Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), and Cohort 3 (4.0 × 10⁶ cells/kg). Escalation proceeds from Cohort 1 to Cohort 3 according to a "3 + 3" algorithm, with each subject receiving a s…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huicun Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New eye drug trial aims to save sight in Hard-to-Treat AMD
Disease control Not yet recruitingType 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is cruc…
Phase: PHASE4 • Sponsor: Kim's Eye Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug PHN-012 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for rare pancreatic cancer: experimental drug enters trial
Disease control ENROLLING_BY_INVITATION* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 …
Phase: PHASE2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Eye implant aims to restore sight in advanced AMD patients
Disease control Recruiting nowThis study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment. This randomized, international, multicenter study will evalu…
Phase: NA • Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktail aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis study is a prospective, exploratory clinical study design, and plans to enroll 33 patients with HR+HER2 low expression breast cancer who received pyrotinib combined with darcili and standard endocrine neoadjuvant therapy to evaluate the efficacy of this regimen in HR+HER2 lo…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill could help control blood disorder when standard drugs fail
Disease control Recruiting nowThis trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon。The study divided into two stages: dose exploration stage: three dose groups …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Scientists hunt for genetic clues to deadly heart side effect of cancer drugs
Knowledge-focused Recruiting nowImmune checkpoint inhibitors (ICI) are active in multiple cancers. Their main drawback is the incidence of immune related adverse events; among which ICI-myocarditis (ICIM) is rare but can be the most life-threatening (up to 50% lethal). ICIM is due to ICI unleashing cytotoxic au…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New app could spot jaundice in newborns with a simple eye photo
Diagnosis Recruiting nowAbout 60% of babies born after 36 weeks of pregnancy have jaundice during the first two weeks of life. Due to the accumulation of bilirubin in the bloodstream, jaundiced babies appear yellow, which allows healthcare professionals to visually identify significantly jaundiced babie…
Sponsor: University College, London • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC